Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02412371 · ClinicalTrials.gov registry record · Phase 1
A Study Evaluating the Efficacy and Tolerability of Veliparib in Combination With Paclitaxel/Carboplatin-Based Chemoradiotherapy Followed by Veliparib and Paclitaxel/Carboplatin Consolidation in Adults With Stage III Non-Small Cell Lung Cancer (NSCLC)
A Phase 1 study, sponsored by AbbVie.
- Terminated
- Registry status
- Phase 1
- Development phase
- 48
- Enrollment target
NCT02412371 is a Phase 1 study that was terminated before completion, run by AbbVie. The registered enrollment target is 48 participants.
The verdict
NCT02412371, a Phase 1 study, was terminated before completion, sponsored by AbbVie.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 48 participants
- Enrollment target
Study Summary
This study seeks to establish * the recommended Phase 2 dose (RPTD) of veliparib in combination with concurrent paclitaxel/carboplatin-based chemoradiotherapy (CRT) and consolidation with paclitaxel/carboplatin-based chemotherapy (Phase 1 portion), and * to assess whether the addition of oral veliparib versus placebo to paclitaxel/carboplatin-based chemoradiotherapy with paclitaxel/carboplatin consolidation will improve progression-free survival (PFS) in adults with Stage III non-small cell lung cancer (Phase 2 portion). A strategy decision was made not to proceed to Phase 2 portion of this study due to change in standard of care.
Interventions
- DRUG Carboplatin
- DRUG Paclitaxel
- RADIATION Radiotherapy
- DRUG Veliparib
- DRUG Placebo for Veliparib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 48 participants |
| Start Date | 2015-04-30 |
| Est. Completion | 2019-08-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02412371
The ClinicalTrials.gov registry entry for NCT02412371 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 48 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AbbVie, which has 526 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Carboplatin is the first listed.
NCT02412371 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02412371 about?
NCT02412371 is a clinical study titled "A Study Evaluating the Efficacy and Tolerability of Veliparib in Combination With Paclitaxel/Carboplatin-Based Chemoradiotherapy Followed by Veliparib and Paclitaxel/Carboplatin Consolidation in Adults With Stage III Non-Small Cell Lung Cancer (NSCLC)". This study seeks to establish * the recommended Phase 2 dose (RPTD) of veliparib in combination with concurrent paclitaxel/carboplatin-based chemoradiotherapy (CRT) and consolidation with paclitaxel/carboplatin-based chemotherapy (Phase 1 portion), and * to assess whether the addition of oral velip...
What is the current status of trial NCT02412371?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 48 participants. The study started on 2015-04-30. Estimated completion is 2019-08-05.
What interventions are being tested in trial NCT02412371?
The interventions under investigation include: Carboplatin (DRUG), Paclitaxel (DRUG), Radiotherapy (RADIATION), Veliparib (DRUG), Placebo for Veliparib (DRUG).
Who is sponsoring clinical trial NCT02412371?
This trial is sponsored by AbbVie, which has 526 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.